23 patents
Utility
Methods and compositions for treating polycystic ovary syndrome
2 Jan 24
Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods.
Christopher Barnes, David Karpf, Mustafa Noor
Filed: 13 Jun 23
Utility
Corticotropin Releasing Factor Receptor Antagonists
28 Dec 23
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 26 Apr 23
Utility
Methods and Compositions for Treating Polycystic Ovary Syndrome
12 Oct 23
Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods.
Christopher BARNES, David KARPF, Mustafa NOOR
Filed: 13 Jun 23
Utility
Corticotropin Releasing Factor Receptor Antagonists
12 Oct 23
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 9 Dec 22
Utility
Methods and Compositions for Treating Polycystic Ovary Syndrome
21 Sep 23
Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods.
Christopher BARNES, David KARPF, Mustafa NOOR
Filed: 9 Feb 23
Utility
Crystalline composition of tildacerfont and methods of use and preparation thereof
25 Jul 23
Dasharatha Reddy, Ashokraj Rajagopal, Lu Wang, Christopher Barnes
Filed: 13 Apr 22
Utility
Crystalline Composition of Tildacerfont and Methods of Use and Preparation Thereof
25 May 23
Dasharatha REDDY, Ashokraj RAJAGOPAL, Lu WANG, Christopher BARNES
Filed: 13 Apr 22
Utility
Corticotropin releasing factor receptor antagonists
7 Jun 22
The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis Howerton, Hal Gerber, Michael Huang
Filed: 25 Jun 21
Utility
Corticotropin releasing factor receptor antagonists
31 May 22
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis Howerton, Hal Gerber, Michael Huang
Filed: 5 Oct 20
Utility
Corticotropin Releasing Factor Receptor Antagonists
12 May 22
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 27 Jan 22
Utility
Methods of Treating Congenital Adrenal Hyperplasia
5 May 22
Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives.
Sangita GHOSH, Christopher BARNES, Michael HUANG
Filed: 18 Jan 22
Utility
Corticotropin releasing factor receptor antagonists
26 Apr 22
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis Howerton, Hal Gerber, Michael Huang
Filed: 25 Jun 21
Utility
Methods for treating testicular and ovarian adrenal rest tumors
19 Apr 22
Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
Alexis Howerton, Hal Gerber
Filed: 27 Oct 20
Utility
Corticotropin Releasing Factor Receptor Antagonists
25 Nov 21
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 14 Aug 18
Utility
Corticotropin Releasing Factor Receptor Antagonists
21 Oct 21
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 25 Jun 21
Utility
Corticotropin Releasing Factor Receptor Antagonists
21 Oct 21
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 25 Jun 21
Utility
Corticotropin releasing factor receptor antagonists
18 May 21
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis Howerton, Hal Gerber, Michael Huang
Filed: 22 Oct 20
Utility
Corticotropin Releasing Factor Receptor Antagonists
13 May 21
The present invention provides novel pharmaceutical compositions comprising 3-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Sami KARABORNI
Filed: 14 Aug 18
Utility
Methods for Treating Testicular and Ovarian Adrenal Rest Tumors
11 Feb 21
Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
Alexis HOWERTON, Hal GERBER
Filed: 27 Oct 20
Utility
Corticotropin Releasing Factor Receptor Antagonists
11 Feb 21
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Alexis HOWERTON, Hal GERBER, Michael HUANG
Filed: 22 Oct 20